• Criptomonedas
  • Mercados de Predicción
  • Noticias
  • Trading Agéntico
  • Artículos
  • Ligas

Buscar Criptomonedas

Criptomonedas de tendencia

CoinRithm

Empresa

Entidad legal
Bees-x Limited
Número de empresa
13308136
Constituida en
England and Wales
Domicilio social
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm es un servicio de información e investigación operado por Bees-x Limited. No está autorizado por la Financial Conduct Authority (FCA) para realizar actividades reguladas, y nada en este sitio constituye asesoramiento financiero.

Explorar

CriptomonedasMercados de PredicciónNoticiasArtículosAgent ArenaLigas

Funciones

TableroComercio SimuladoTrading AgénticoPortafolioLista de SeguimientoConfiguraciones

Empresa

Sobre NosotrosMetodologiaTérminos de UsoPolítica de PrivacidadPolítica de CookiesDescargo de Responsabilidad

Soporte

Contacto SoporteFAQKit para desarrolladoresDocumentación MCP

Sociales

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Reservados todos los derechos.
Disponible en Google PlayDescargar en App Store
  • Inicio
  • MercadosMercados de Predicción
  • Noticias
  • Tablero
  1. Mercados de Predicción
  2. Health & Medicine
  3. Will the FDA approve any psychedelic substance for medical use this year?
Will the FDA approve any psychedelic substance for medical use this year?

Will the FDA approve any psychedelic substance for medical use this year?

5.0% (24h)Health & MedicineOne-Off6m
KalshiKalshiComprobar disponibilidadKYC requerido2% de comisión
Probabilidad implícita actual
Sí
Sí 32%-5.0%
Calidad del mercado

28 / 100

Baja calidad
Volumen 24h

12 €

Liquidez

712,5 €

Baja liquidez
Compra / Venta

30.0% / 33.0%

Spread

10.0%

Spread amplio
Datos de mercado

Actualizado hace 3 minutos

17 jul 25, 14:001 ene 27, 4:59

Tendencias

Resultado24hProbabilidad

Resultado elegido

Yes32%

Reglas

If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.

Kalshi
  • Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.
  • Important information: For purposes of this Contract:
  • The listed substances are illustrative, not exhaustive.
  • Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.
  • "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product.

Mercados Relacionados

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3 mil €
Sí: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6 mil €
Sí: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7 mil €
Sí: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3 mil €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Activos en estos temas

BitcoinBTC$62,867.10+2.52%EthereumETH$1,658.07+1.88%SolanaSOL$65.28+1.86%DogecoinDOGE$0.085+1.73%XRPXRP$1.12+0.74%BNBBNB$596.82+1.84%

Noticias Relacionadas

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Reglas

If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.

Kalshi
  • Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.
  • Important information: For purposes of this Contract:
  • The listed substances are illustrative, not exhaustive.
  • Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.
  • "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product.